ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Nelson Vergel is Seeking Input: Tell the FDA to Stop Attacking Compounded Hormones
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 259071" data-attributes="member: 13851"><p><strong>Content Current as of 12/29/2022</strong></p><p></p><p>[URL unfurl="true"]https://www.fda.gov/drugs/human-drug-compounding/safety-risks-associated-certain-bulk-drug-substances-nominated-use-compounding[/URL]</p><p></p><h3>Summary of the Safety Risks</h3> <table class='post-table ' style='width: 100%'><tr><th ><p>Category 2 substance</p></th><th ><p>Nominated with sufficient information under 503A or 503B or both</p></th><th ><p>Date added to Category 2</p></th><th ><p>Safety risks</p></th></tr></table>[ATTACH=full]34339[/ATTACH]</p><p></p><p></p><p></p><p>[URL unfurl="true"]https://pubmed.ncbi.nlm.nih.gov/21067829/[/URL]</p><p></p><p></p><p></p><p></p><p>What a joke!</p><p></p><p>This sums it up.</p><p></p><p><em>*Merck began searching for a nonpeptide mimetic that had a high oral bioavailability and pharmacokinetics that would allow for once-daily oral administration. 14 A breakthrough occurred when L-692,429 was discovered as it showed that it was possible to design a small molecule peptidomimetic agonist for GHRP6. 14 While this molecule had an improved oral bioavailability, the pharmacokinetic properties did not allow for a once-daily oral administration. 14 <strong>Continued modifications led to the development of L-163,191 which was shown to have “<u>excellent potency, selectivity, and oral bioavailability, as well as appropriate pharmacokinetics suitable for once daily oral dosing” and with continued research found “to have an excellent safety profile</u>.”14 <u>This led to the clinical development of L-163,191 as MK-0677, or ibutamoren mesylate</u>. 9,14 </strong></em></p><p></p><p></p><p></p><p></p><p>[URL unfurl="true"]https://archive.hshsl.umaryland.edu/handle/10713/14872[/URL]</p><p></p><p></p><p><strong>Ibutamoren mesylate: Summary Report</strong></p><p><strong></strong></p><p><strong>INTRODUCTION </strong></p><p></p><p><em>This report was created to assist the Food and Drug Administration (FDA) in their evaluation of the use of ibutamoren mesylate (also known as MK-0677 or MK-677) (UNII code: GJ0EGN38UL) which was nominated for use as a bulk drug substance in compounding by outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act. </em></p><p><em></em></p><p><em><strong><em>The aim of this report was to describe how ibutamoren mesylate is used in clinical research and practice to diagnose, prevent, or treat disease. Due to the broad, exploratory nature of this aim, scoping review methodology was used.</em></strong> Following the scoping review framework, a systematic literature review was conducted and healthcare practitioners were consulted to identify how ibutamoren mesylate has been used historically and currently. 1-3 Assessment of study quality and risk of bias were not performed because the aim of this report was not to make specific recommendations on the use of this substance in clinical practice.1,4,5 <strong>Rather, the aim was to summarize the available evidence on the use of ibutamoren mesylate and thereby assist the FDA to determine whether there is a need for the inclusion of this substance on the 503B Bulks List</strong></em></p><p></p><p></p><p></p><p></p><p><strong>CURRENT AND HISTORIC USE</strong></p><p></p><p> <strong>Results of background information</strong></p><p></p><p>• Ibutamoren mesylate is not available as an FDA-approved product in the nominated dosage form and ROA.</p><p>• Ibutamoren mesylate is not available as an OTC product in the US.</p><p>• There is no current United States Pharmacopeia (USP) monograph for ibutamoren mesylate.</p><p>• Ibutamoren mesylate is not available in the nominated dosage form and ROA in any of the foreign registries searched.</p><p></p><p></p><p></p><p></p><p><strong>Use of ibutamoren mesylate:</strong></p><p></p><p><em><strong>Three hundred ten patients received ibutamoren mesylate as an experimental treatment for bone formation and resorption,</strong> administered orally in doses ranging from 5 mg to 50 mg. Duration of treatment ranged from 14 days to 18 months. </em></p><p><em></em></p><p><em><strong>Two hundred eighty-two patients received ibutamoren mesylate as an experimental treatment for Alzheimer’s disease,</strong> administered orally at a dose of 25 mg. Duration of treatment was 12 months.</em></p><p><em></em></p><p><em><strong>One hundred forty-six patients received ibutamoren mesylate as an experimental treatment for posthip fracture surgery,</strong> administered orally at a dose of 25 mg. Duration of treatment was 6 months. </em></p><p><em></em></p><p><em><strong>Sixty-two patients received ibutamoren mesylate as an experimental treatment to prevent the decline in fat-free mass and to decrease abdominal visceral fat,</strong> administered orally at a dose of 25 mg. Duration of treatment ranged from 1 to 2 years. </em></p><p><em></em></p><p><em><strong>Twenty-two patients received ibutamoren mesylate as an experimental treatment to improve nutritional status in end-stage renal disease (ESRD),</strong> administered orally at a dose of 25 mg. Duration of treatment was 3 months. </em></p><p><em></em></p><p><em><strong>Twenty-two patients received ibutamoren mesylate as an experimental treatment for use in older adults,</strong> administered orally in doses ranging from 2 mg to 25 mg. Duration of treatment was 42 days. </em></p><p><em></em></p><p><em><strong>An unknown number of hypogonadal men on testosterone therapy received ibutamoren mesylate for reduction of body fat mass and increase in skeletal muscle mass</strong> at an unknown dose and duration of treatment.</em></p><p><em></em></p><p><em><strong>Eighteen patients received ibutamoren mesylate as an experimental treatment in children with GHD,</strong> administered orally in doses ranging from 0.2 mg/kg/day to 0.8 mg/kg/day. Duration of treatment was 15 days. </em></p><p><em></em></p><p><em><strong>Fifteen patients received ibutamoren mesylate as an experimental treatment to improve sleep quality, </strong>administered orally at a dose ranging from 2 mg to 25 mg. Duration of treatment ranged from 21 days to 28 days. </em></p><p><em></em></p><p><em><strong>Twelve patients received ibutamoren mesylate as an experimental treatment for use in obese patients,</strong> administered orally at a dose of 25 mg. Duration of treatment was 8 weeks. 10</em></p><p><em></em></p><p><em><strong>Eight patients received ibutamoren mesylate as an experimental treatment to reverse the catabolic response to dietary energy restriction,</strong> administered orally at a dose of 25 mg. Duration of treatment was 28 days. </em></p><p><em></em></p><p><em><strong>Five patients received ibutamoren mesylate as an experimental treatment in adults with GH deficiency,</strong> administered orally in doses ranging from 10 mg to 50 mg. Duration of treatment was 8 days. </em></p><p><em></em></p><p><em><strong>Refer to Tables 6 and 7 for summaries of dosage by indication. </strong></em></p><p><em></em></p><p><em>Ibutamoren was not used as a compounded product, nor was it used in a combination product.</em></p><p><em></em></p><p><em><strong><em>In 12 studies, the authors concluded that further studies were necessary for the use of ibutamoren mesylate in the treatment of GHD of childhood-onset, to increase bone mass and reduce risk of fractures, to improve nutritional status in patients with ESRD, to promote a reduction in body fat in obese patients, to decrease LDL-C concentrations, in the treatment of conditions associated with GHD in older adults, to prevent the decline in fat-free mass and to decrease abdominal visceral fat, in the rehabilitation of patients post-hip fracture, in the treatment of catabolic patients secondary to acute or chronic disease states, and to improve sleep quality. In 3 studies, the authors’ concluding statement did not provide a recommendation regarding use of ibutamoren mesylate to promote bone formation and resorption and to modify body composition and total body fat. In 2 studies, the authors’ concluding statement did not recommend the use of ibutamoren mesylate to improve overall physical functional performance in patients post-hip fracture surgery and to slow the rate of progression of Alzheimer’s disease.</em></strong></em></p><p></p><p></p><p></p><p></p><p><strong>Pharmacology and historical use </strong></p><p></p><p><em>Several studies were identified that did not meet the inclusion criteria but provided valuable information about the pharmacology and historical use of ibutamoren mesylate. </em></p><p><em></em></p><p><em>Growth hormone (GH), also known as somatotropin, is a protein that is produced by the somatotroph cells found in the anterior lobe of the pituitary gland. <strong>GH receptors are found throughout the body and are responsible for many metabolic functions including promoting growth in children, increasing lipolysis, stimulating protein synthesis, and antagonizing insulin.9</strong> GH is regulated by 3 hypothalamic hormones: growth hormone-releasing hormone (GHRH), somatostatin, and ghrelin.11 <strong>GHRH and ghrelin stimulate GH release while somatostatin inhibits release. 11</strong> <strong>GH has a pulsatile secretion with production occurring primarily at night and pulses following exercise, trauma, and sleep.9</strong> GH production rises in childhood with the peak occurring at puberty and then declines with age. <strong>As GH declines with age, exogenous administration has many proposed benefits including increasing lean muscle mass, decreasing fat mass, increasing exercise tolerance, and increasing muscle strength.9 However, due to potential safety concerns associated with supratherapeutic GH levels resulting from the bypass of the normal, regulatory feedback, there has been an interest in the use of GH secretagogues.9,12 </strong></em></p><p><em></em></p><p><em>GH secretagogues include GH-releasing peptides (GHRPs), like GHRP2 and GHRP6, and GHRH analogs, like sermorelin. <strong>GH secretagogues stimulate the endogenous secretion of GH, GHRPs increase the number of somatotrophs releasing GH, and GHRH analogs increase the amount of GH secreted, which maintains levels within normal physiologic levels.9,13</strong> <strong>The action of GHRPs is independent of GHRH so as a result, when a GHRH analog and a GHRP are used together they have a synergistic effect stimulating the release of GH.9,12 11 </strong></em></p><p><em></em></p><p><em>GHRPs were first synthesized in 1977 and GHRP6 was the first that was found to have significant in vivo activity; however, due to its poor oral bioavailability and short half-life, it had to be administered frequently and as an injection.9 Additionally, “as a peptide it did not lend itself to the optimization of pharmacokinetic properties”. 14 <strong>Due to these challenges, using GHRP6 as a model structure, Merck began searching for a nonpeptide mimetic that had a high oral bioavailability and pharmacokinetics that would allow for once-daily oral administration. 14 A breakthrough occurred when L-692,429 was discovered as it showed that it was possible to design a small molecule peptidomimetic agonist for GHRP6. 14 While this molecule had an improved oral bioavailability, the pharmacokinetic properties did not allow for a once-daily oral administration. 14 Continued modifications led to the development of L-163,191 which was shown to have “<u>excellent potency, selectivity, and oral bioavailability, as well as appropriate pharmacokinetics suitable for once daily oral dosing</u>” and with continued research found “<u>to have an excellent safety profile</u>.”14 <u>This led to the clinical development of L-163,191 as MK-0677, or ibutamoren mesylate</u>. 9,14 </strong></em></p><p><em><strong></strong></em></p><p><em><strong>Ibutamoren mesylate binds to the ghrelin receptor and was found to not only enhance the pulsatile release of GH but also act as an antagonist to somatostatin allowing for GH levels to remain elevated for up to 360 minutes after a single oral dose.13,15 </strong>In 1996, Chapman et al studied the effects of 2 mg, 10 mg, and 25 mg of MK-677 administered orally once daily compared to placebo in 32 healthy adults between the ages of 64-81 years. 16 Patients were randomized to receive either MK-677 or placebo; GH and IGF-1, a surrogate blood marker for GH, levels were measured. After 2 weeks, GH and IGF-1 levels in the 10 mg and 25 mg MK-677 groups were significantly increased compared at baseline in a dose-dependent manner; participants that received 25 mg of MK-677 had IGF-1 levels restored to normal levels seen in young adults. Additionally, it was found that the GH increase was due to enhanced pulsatile GH secretion and not an increase in the number of pulses. <strong>This was the first study to show that daily administration of a GH secretagogue could increase GH and IGF-1 levels in older adults.16 </strong></em></p><p><em></em></p><p><em>Copinschi et al evaluated the use of 5 mg and 25 mg of MK-677 compared to placebo in 9 healthy males between the ages of 18-30 years to evaluate the effect on pulsatile GH secretion, IGF-1 levels, and adrenocortical function. 17 Additionally, the medication was taken at night to determine whether it would enhance the physiological release of GH that occurs at night.17 The study found that the amount of GH secreted was similar in all 3 groups; however, in the MK-677 groups, the number of GH pulses was increased. IGF-1 levels were also increased, in a dose-dependent manner, in the MK677 groups compared to placebo. <strong>This study concluded that the use of “MK-677 for the treatment of relative somatotrophic deficiency, particular in older adults compromised by such deficiency, deserves further investigation.”17 </strong></em></p><p><em></em></p><p><em>Several studies were conducted evaluating the use of ibutamoren mesylate in various disease states and<strong> Merck was developing the drug for FDA approval for use in GH deficient children, recovery of hip fractures, and to treat the frail elderly; however, Merck discontinued its development in 1999. 18 After Merck discontinued development, Ammonett Pharma LLC continued to develop MK-0677 for treatment of GHDin children and in 2017 received a designated orphan status from FDA for treatment of GHD. 19 In 2018, Lumos Pharma, Inc acquired the license for MK-0677 from Ammonett Pharma LLC, renamed it LUM-201, and is currently developing it for treatment of pediatric GHD, Turner Syndrome, and children born small for gestational age (SGA).20 Lumos Pharma, Inc is currently recruiting participants for a multi-national, phase 2 study of LUM-201 in pediatric GHD (the OraGrowtH210 Trial) with expected results in mid-2022. 20,21</strong></em></p><p></p><p></p><p></p><p></p><p><strong>CONCLUSION</strong><em> </em></p><p><em></em></p><p><em>Ibutamoren mesylate was nominated for inclusion on the 503B Bulks List as an oral capsule to treat GHD and catabolic conditions.<strong> Ibutamoren mesylate is not available in the nominated dosage forms and ROA in any of the national medical registries searched.</strong></em></p><p></p><p> <em>From the literature review, ibutamoren mesylate has been studied to treat GHD as well as use in various conditions associated with declining GH levels, including post-hip fracture surgery to facilitate the rehabilitation process, to improve anthropomorphic parameters, to improve the nutritional status in patients with ESRD, to promote bone formation and resorption, Alzheimer’s disease, to improve sleep quality, to reverse the catabolic response to dietary energy restrictions, and use in obese patients. <strong>All of the studies utilized ibutamoren mesylate as a once-daily product with doses ranging from 2 mg to 50 mg. <u>None of the authors’ recommended the routine use of ibutamoren mesylate, however, several studies reported positive preliminary results concluding that additional studies are warranted</u>. Ibutamoren mesylate has a designated orphan drug status for treatment of GHD and is currently being developed by Lumos Pharma, Inc under then name LUM-201. Lumos Pharma, Inc is currently recruiting participants for a multi-national, phase 2 study of LUM-201 in pediatric GHD (the OraGrowtH210 Trial) with expected results in mid-2022. </strong></em></p><p><em><strong></strong></em></p><p><em><strong>From the interviews conducted, only 2 SMEs were familiar with ibutamoren mesylate. However, a third SME stated that there would be a need for it in catabolic conditions if it worked. </strong>Ibutamoren was being developed by Merck, but after 20 years of research, they decided to close the program. <strong>Recent interest has led to ibutamoren being developed for use in children with GHD and one SME hoped that it will be approved for use in children in the next 2-3 years. <u>Ibutamoren mesylate is also used as a “lifestyle medication” for patients that want to “feel better” and “try to mitigate muscle loss</u>.” <u>Since it was being developed by Merck, there is a lot of initial clinical trial data “showing that it can be very beneficial” and outline a clear dosing regimen</u>. The 2 SMEs that were familiar with ibutamoren mesylated differed in their opinions on compounding ibutamoren. <u>One SME stated that while it is a “fantastic drug” and is “pretty safe,” since the API is not available did not see any way that it could be compounded</u>. <u>The other SME said that since GH secretagogues, including ibutamoren mesylate, are not currently approved for use the only way to obtain them is through a compounding pharmacy</u>. </strong></em></p><p><em></em></p><p><em>Zero people responded to the survey distributed via professional medical associations and available on the project website.</em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em>[ATTACH=full]34329[/ATTACH]</em></p><p><em>[ATTACH=full]34330[/ATTACH]</em></p><p><em>[ATTACH=full]34331[/ATTACH]</em></p><p><em>[ATTACH=full]34332[/ATTACH]</em></p><p><em>[ATTACH=full]34333[/ATTACH]</em></p><p><em>[ATTACH=full]34334[/ATTACH]</em></p><p><em>[ATTACH=full]34335[/ATTACH]</em></p></blockquote><p></p>
[QUOTE="madman, post: 259071, member: 13851"] [B]Content Current as of 12/29/2022[/B] [URL unfurl="true"]https://www.fda.gov/drugs/human-drug-compounding/safety-risks-associated-certain-bulk-drug-substances-nominated-use-compounding[/URL] [HEADING=2]Summary of the Safety Risks[/HEADING] [TABLE][TR][TH]Category 2 substance[/TH] [TH]Nominated with sufficient information under 503A or 503B or both[/TH] [TH]Date added to Category 2[/TH] [TH]Safety risks[/TH][/TR][/TABLE] [ATTACH type="full" alt="Screenshot (26084).png"]34339[/ATTACH] [URL unfurl="true"]https://pubmed.ncbi.nlm.nih.gov/21067829/[/URL] What a joke! This sums it up. [I]*Merck began searching for a nonpeptide mimetic that had a high oral bioavailability and pharmacokinetics that would allow for once-daily oral administration. 14 A breakthrough occurred when L-692,429 was discovered as it showed that it was possible to design a small molecule peptidomimetic agonist for GHRP6. 14 While this molecule had an improved oral bioavailability, the pharmacokinetic properties did not allow for a once-daily oral administration. 14 [B]Continued modifications led to the development of L-163,191 which was shown to have “[U]excellent potency, selectivity, and oral bioavailability, as well as appropriate pharmacokinetics suitable for once daily oral dosing” and with continued research found “to have an excellent safety profile[/U].”14 [U]This led to the clinical development of L-163,191 as MK-0677, or ibutamoren mesylate[/U]. 9,14 [/B][/I] [URL unfurl="true"]https://archive.hshsl.umaryland.edu/handle/10713/14872[/URL] [B]Ibutamoren mesylate: Summary Report INTRODUCTION [/B] [I]This report was created to assist the Food and Drug Administration (FDA) in their evaluation of the use of ibutamoren mesylate (also known as MK-0677 or MK-677) (UNII code: GJ0EGN38UL) which was nominated for use as a bulk drug substance in compounding by outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act. [B][I]The aim of this report was to describe how ibutamoren mesylate is used in clinical research and practice to diagnose, prevent, or treat disease. Due to the broad, exploratory nature of this aim, scoping review methodology was used.[/I][/B] Following the scoping review framework, a systematic literature review was conducted and healthcare practitioners were consulted to identify how ibutamoren mesylate has been used historically and currently. 1-3 Assessment of study quality and risk of bias were not performed because the aim of this report was not to make specific recommendations on the use of this substance in clinical practice.1,4,5 [B]Rather, the aim was to summarize the available evidence on the use of ibutamoren mesylate and thereby assist the FDA to determine whether there is a need for the inclusion of this substance on the 503B Bulks List[/B][/I] [B]CURRENT AND HISTORIC USE[/B] [B]Results of background information[/B] • Ibutamoren mesylate is not available as an FDA-approved product in the nominated dosage form and ROA. • Ibutamoren mesylate is not available as an OTC product in the US. • There is no current United States Pharmacopeia (USP) monograph for ibutamoren mesylate. • Ibutamoren mesylate is not available in the nominated dosage form and ROA in any of the foreign registries searched. [B]Use of ibutamoren mesylate:[/B] [I][B]Three hundred ten patients received ibutamoren mesylate as an experimental treatment for bone formation and resorption,[/B] administered orally in doses ranging from 5 mg to 50 mg. Duration of treatment ranged from 14 days to 18 months. [B]Two hundred eighty-two patients received ibutamoren mesylate as an experimental treatment for Alzheimer’s disease,[/B] administered orally at a dose of 25 mg. Duration of treatment was 12 months. [B]One hundred forty-six patients received ibutamoren mesylate as an experimental treatment for posthip fracture surgery,[/B] administered orally at a dose of 25 mg. Duration of treatment was 6 months. [B]Sixty-two patients received ibutamoren mesylate as an experimental treatment to prevent the decline in fat-free mass and to decrease abdominal visceral fat,[/B] administered orally at a dose of 25 mg. Duration of treatment ranged from 1 to 2 years. [B]Twenty-two patients received ibutamoren mesylate as an experimental treatment to improve nutritional status in end-stage renal disease (ESRD),[/B] administered orally at a dose of 25 mg. Duration of treatment was 3 months. [B]Twenty-two patients received ibutamoren mesylate as an experimental treatment for use in older adults,[/B] administered orally in doses ranging from 2 mg to 25 mg. Duration of treatment was 42 days. [B]An unknown number of hypogonadal men on testosterone therapy received ibutamoren mesylate for reduction of body fat mass and increase in skeletal muscle mass[/B] at an unknown dose and duration of treatment. [B]Eighteen patients received ibutamoren mesylate as an experimental treatment in children with GHD,[/B] administered orally in doses ranging from 0.2 mg/kg/day to 0.8 mg/kg/day. Duration of treatment was 15 days. [B]Fifteen patients received ibutamoren mesylate as an experimental treatment to improve sleep quality, [/B]administered orally at a dose ranging from 2 mg to 25 mg. Duration of treatment ranged from 21 days to 28 days. [B]Twelve patients received ibutamoren mesylate as an experimental treatment for use in obese patients,[/B] administered orally at a dose of 25 mg. Duration of treatment was 8 weeks. 10 [B]Eight patients received ibutamoren mesylate as an experimental treatment to reverse the catabolic response to dietary energy restriction,[/B] administered orally at a dose of 25 mg. Duration of treatment was 28 days. [B]Five patients received ibutamoren mesylate as an experimental treatment in adults with GH deficiency,[/B] administered orally in doses ranging from 10 mg to 50 mg. Duration of treatment was 8 days. [B]Refer to Tables 6 and 7 for summaries of dosage by indication. [/B] Ibutamoren was not used as a compounded product, nor was it used in a combination product. [B][I]In 12 studies, the authors concluded that further studies were necessary for the use of ibutamoren mesylate in the treatment of GHD of childhood-onset, to increase bone mass and reduce risk of fractures, to improve nutritional status in patients with ESRD, to promote a reduction in body fat in obese patients, to decrease LDL-C concentrations, in the treatment of conditions associated with GHD in older adults, to prevent the decline in fat-free mass and to decrease abdominal visceral fat, in the rehabilitation of patients post-hip fracture, in the treatment of catabolic patients secondary to acute or chronic disease states, and to improve sleep quality. In 3 studies, the authors’ concluding statement did not provide a recommendation regarding use of ibutamoren mesylate to promote bone formation and resorption and to modify body composition and total body fat. In 2 studies, the authors’ concluding statement did not recommend the use of ibutamoren mesylate to improve overall physical functional performance in patients post-hip fracture surgery and to slow the rate of progression of Alzheimer’s disease.[/I][/B][/I] [B]Pharmacology and historical use [/B] [I]Several studies were identified that did not meet the inclusion criteria but provided valuable information about the pharmacology and historical use of ibutamoren mesylate. Growth hormone (GH), also known as somatotropin, is a protein that is produced by the somatotroph cells found in the anterior lobe of the pituitary gland. [B]GH receptors are found throughout the body and are responsible for many metabolic functions including promoting growth in children, increasing lipolysis, stimulating protein synthesis, and antagonizing insulin.9[/B] GH is regulated by 3 hypothalamic hormones: growth hormone-releasing hormone (GHRH), somatostatin, and ghrelin.11 [B]GHRH and ghrelin stimulate GH release while somatostatin inhibits release. 11[/B] [B]GH has a pulsatile secretion with production occurring primarily at night and pulses following exercise, trauma, and sleep.9[/B] GH production rises in childhood with the peak occurring at puberty and then declines with age. [B]As GH declines with age, exogenous administration has many proposed benefits including increasing lean muscle mass, decreasing fat mass, increasing exercise tolerance, and increasing muscle strength.9 However, due to potential safety concerns associated with supratherapeutic GH levels resulting from the bypass of the normal, regulatory feedback, there has been an interest in the use of GH secretagogues.9,12 [/B] GH secretagogues include GH-releasing peptides (GHRPs), like GHRP2 and GHRP6, and GHRH analogs, like sermorelin. [B]GH secretagogues stimulate the endogenous secretion of GH, GHRPs increase the number of somatotrophs releasing GH, and GHRH analogs increase the amount of GH secreted, which maintains levels within normal physiologic levels.9,13[/B] [B]The action of GHRPs is independent of GHRH so as a result, when a GHRH analog and a GHRP are used together they have a synergistic effect stimulating the release of GH.9,12 11 [/B] GHRPs were first synthesized in 1977 and GHRP6 was the first that was found to have significant in vivo activity; however, due to its poor oral bioavailability and short half-life, it had to be administered frequently and as an injection.9 Additionally, “as a peptide it did not lend itself to the optimization of pharmacokinetic properties”. 14 [B]Due to these challenges, using GHRP6 as a model structure, Merck began searching for a nonpeptide mimetic that had a high oral bioavailability and pharmacokinetics that would allow for once-daily oral administration. 14 A breakthrough occurred when L-692,429 was discovered as it showed that it was possible to design a small molecule peptidomimetic agonist for GHRP6. 14 While this molecule had an improved oral bioavailability, the pharmacokinetic properties did not allow for a once-daily oral administration. 14 Continued modifications led to the development of L-163,191 which was shown to have “[U]excellent potency, selectivity, and oral bioavailability, as well as appropriate pharmacokinetics suitable for once daily oral dosing[/U]” and with continued research found “[U]to have an excellent safety profile[/U].”14 [U]This led to the clinical development of L-163,191 as MK-0677, or ibutamoren mesylate[/U]. 9,14 Ibutamoren mesylate binds to the ghrelin receptor and was found to not only enhance the pulsatile release of GH but also act as an antagonist to somatostatin allowing for GH levels to remain elevated for up to 360 minutes after a single oral dose.13,15 [/B]In 1996, Chapman et al studied the effects of 2 mg, 10 mg, and 25 mg of MK-677 administered orally once daily compared to placebo in 32 healthy adults between the ages of 64-81 years. 16 Patients were randomized to receive either MK-677 or placebo; GH and IGF-1, a surrogate blood marker for GH, levels were measured. After 2 weeks, GH and IGF-1 levels in the 10 mg and 25 mg MK-677 groups were significantly increased compared at baseline in a dose-dependent manner; participants that received 25 mg of MK-677 had IGF-1 levels restored to normal levels seen in young adults. Additionally, it was found that the GH increase was due to enhanced pulsatile GH secretion and not an increase in the number of pulses. [B]This was the first study to show that daily administration of a GH secretagogue could increase GH and IGF-1 levels in older adults.16 [/B] Copinschi et al evaluated the use of 5 mg and 25 mg of MK-677 compared to placebo in 9 healthy males between the ages of 18-30 years to evaluate the effect on pulsatile GH secretion, IGF-1 levels, and adrenocortical function. 17 Additionally, the medication was taken at night to determine whether it would enhance the physiological release of GH that occurs at night.17 The study found that the amount of GH secreted was similar in all 3 groups; however, in the MK-677 groups, the number of GH pulses was increased. IGF-1 levels were also increased, in a dose-dependent manner, in the MK677 groups compared to placebo. [B]This study concluded that the use of “MK-677 for the treatment of relative somatotrophic deficiency, particular in older adults compromised by such deficiency, deserves further investigation.”17 [/B] Several studies were conducted evaluating the use of ibutamoren mesylate in various disease states and[B] Merck was developing the drug for FDA approval for use in GH deficient children, recovery of hip fractures, and to treat the frail elderly; however, Merck discontinued its development in 1999. 18 After Merck discontinued development, Ammonett Pharma LLC continued to develop MK-0677 for treatment of GHDin children and in 2017 received a designated orphan status from FDA for treatment of GHD. 19 In 2018, Lumos Pharma, Inc acquired the license for MK-0677 from Ammonett Pharma LLC, renamed it LUM-201, and is currently developing it for treatment of pediatric GHD, Turner Syndrome, and children born small for gestational age (SGA).20 Lumos Pharma, Inc is currently recruiting participants for a multi-national, phase 2 study of LUM-201 in pediatric GHD (the OraGrowtH210 Trial) with expected results in mid-2022. 20,21[/B][/I] [B]CONCLUSION[/B][I] Ibutamoren mesylate was nominated for inclusion on the 503B Bulks List as an oral capsule to treat GHD and catabolic conditions.[B] Ibutamoren mesylate is not available in the nominated dosage forms and ROA in any of the national medical registries searched.[/B][/I] [I]From the literature review, ibutamoren mesylate has been studied to treat GHD as well as use in various conditions associated with declining GH levels, including post-hip fracture surgery to facilitate the rehabilitation process, to improve anthropomorphic parameters, to improve the nutritional status in patients with ESRD, to promote bone formation and resorption, Alzheimer’s disease, to improve sleep quality, to reverse the catabolic response to dietary energy restrictions, and use in obese patients. [B]All of the studies utilized ibutamoren mesylate as a once-daily product with doses ranging from 2 mg to 50 mg. [U]None of the authors’ recommended the routine use of ibutamoren mesylate, however, several studies reported positive preliminary results concluding that additional studies are warranted[/U]. Ibutamoren mesylate has a designated orphan drug status for treatment of GHD and is currently being developed by Lumos Pharma, Inc under then name LUM-201. Lumos Pharma, Inc is currently recruiting participants for a multi-national, phase 2 study of LUM-201 in pediatric GHD (the OraGrowtH210 Trial) with expected results in mid-2022. From the interviews conducted, only 2 SMEs were familiar with ibutamoren mesylate. However, a third SME stated that there would be a need for it in catabolic conditions if it worked. [/B]Ibutamoren was being developed by Merck, but after 20 years of research, they decided to close the program. [B]Recent interest has led to ibutamoren being developed for use in children with GHD and one SME hoped that it will be approved for use in children in the next 2-3 years. [U]Ibutamoren mesylate is also used as a “lifestyle medication” for patients that want to “feel better” and “try to mitigate muscle loss[/U].” [U]Since it was being developed by Merck, there is a lot of initial clinical trial data “showing that it can be very beneficial” and outline a clear dosing regimen[/U]. The 2 SMEs that were familiar with ibutamoren mesylated differed in their opinions on compounding ibutamoren. [U]One SME stated that while it is a “fantastic drug” and is “pretty safe,” since the API is not available did not see any way that it could be compounded[/U]. [U]The other SME said that since GH secretagogues, including ibutamoren mesylate, are not currently approved for use the only way to obtain them is through a compounding pharmacy[/U]. [/B] Zero people responded to the survey distributed via professional medical associations and available on the project website. [ATTACH type="full" alt="Screenshot (26074).png"]34329[/ATTACH] [ATTACH type="full" alt="Screenshot (26075).png"]34330[/ATTACH] [ATTACH type="full" alt="Screenshot (26076).png"]34331[/ATTACH] [ATTACH type="full" alt="Screenshot (26077).png"]34332[/ATTACH] [ATTACH type="full" alt="Screenshot (26078).png"]34333[/ATTACH] [ATTACH type="full" alt="Screenshot (26079).png"]34334[/ATTACH] [ATTACH type="full" alt="Screenshot (26080).png"]34335[/ATTACH][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Nelson Vergel is Seeking Input: Tell the FDA to Stop Attacking Compounded Hormones
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top